Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 848 across all filing types
Latest filing 2019-08-07 Regulatory Filings
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-08-07 English
424B3
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a proxy statement/prospectus/information statement filed pursuant to Rule 424(b)(3) related to a proposed merger between Histogenics Corporation and Ocugen, Inc. It includes detailed information about the merger agreement, voting procedures, special meeting notices, and related corporate actions such as reverse stock split and amendments to the certificate of incorporation. The document is clearly focused on merger-related shareholder voting and solicitation of proxies, which aligns with materials sent to shareholders to provide information and request votes for meetings. It is not a full merger agreement filing (like Form 425 or DEFM14A), nor is it a simple announcement or regulatory filing. The presence of detailed voting proposals and meeting notices indicates it is a Proxy Solicitation & Information Statement (PSI).
2019-08-06 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from Histogenics Corporation to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-4. It references Rule 461 of Regulation C under the Securities Act of 1933 and requests the SEC to make the Form S-4 effective by a certain date and time. The document is a formal correspondence related to a regulatory filing process, specifically about the effectiveness of a registration statement for a merger or acquisition transaction (Form S-4 is used for securities registration in business combinations). The document does not contain financial statements, audit information, or detailed report content. It is a regulatory procedural letter related to a merger/acquisition filing but is not the merger filing itself. Given the nature and length (1931 characters), it is not a full report but a regulatory filing correspondence. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement related to the registration statement effectiveness request.
2019-08-02 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm responding to comments from the SEC staff regarding an Amendment No. 1 to a Registration Statement on Form S-4 filed by Histogenics Corporation. It discusses pro forma financial statement adjustments related to a merger or acquisition transaction. The document is correspondence related to a regulatory filing (Form S-4) amendment and does not contain actual financial statements or a full report. It is not an Annual Report, Interim Report, or any other financial report type. It is also not a report publication announcement since it is substantive correspondence with the SEC. The document fits best under Regulatory Filings (RNS) as it is a regulatory correspondence letter responding to SEC comments on a registration statement amendment.
2019-08-02 English
S-4/A
Merger & Acquisition Classification · 95% confidence The document is a Form S-4/A Registration Statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It includes detailed information about a proposed merger between Histogenics Corporation and Ocugen, Inc., including the merger agreement, stock issuance, reverse stock split, and shareholder meeting details. The document is not a financial report like an annual or quarterly report, nor is it a simple announcement or proxy solicitation. It is a comprehensive filing related to a merger transaction and securities registration. Therefore, it fits best under the category of Merger & Acquisition filings (MA). The document length and content confirm it is the actual filing, not just an announcement or proxy statement.
2019-08-02 English
Regulatory Filings 2019
Regulatory Filings
2019-07-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.